Ascendis Pharma Receives Positive CHMP Opinion for TransCon CNP in Achondroplasia

Key Facts

1TransCon CNP (navepegritide) received a positive opinion from the European Medicines Agency's CHMP for marketing authorization.

2The treatment is indicated for children aged two years and older with achondroplasia whose epiphyses are not closed.

3A final European Commission decision on the Marketing Authorisation Application is expected during Q4 2026.

Ascendis Pharma's TransCon CNP (navepegritide) received a positive opinion from the European Medicines Agency's CHMP for marketing authorization. GlobeNewswire reported that the treatment is indicated for children aged two years and older with achondroplasia whose epiphyses are not closed. A final European Commission decision on the Marketing Authorisation Application is expected during the fourth quarter of 2026.

ASND closed at $226.62 on October 15, 2026, with the stock trading between a day low of $226.06 and a high of $234.01 during that session. This regulatory milestone is a critical step toward commercializing the drug in the European Union, where the company anticipates its first launch under the brand name YUVIWEL in Germany during the first quarter of 2027, pending final authorization.